Biological
Tozinameran
Tozinameran is a biological therapy with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
33%
Ph phase_3
1
17%
Ph phase_4
2
33%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed2
Not yet recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
Trials by Status
unknown233%
not_yet_recruiting117%
completed233%
withdrawn117%
Recent Activity
0 active trials
Showing 5 of 6
not_yet_recruitingphase_2
Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients
NCT07390968
completedphase_4
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
NCT05406908
withdrawnphase_3
COVID-19 Fourth Dose Study in Australia
NCT05543356
unknownphase_2
Covid-19 Vaccination in Adolescents and Children
NCT04800133
completedphase_4
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
NCT05168709
Clinical Trials (6)
Showing 6 of 6 trials
NCT07390968Phase 2
Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients
NCT05406908Phase 4
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
NCT05543356Phase 3
COVID-19 Fourth Dose Study in Australia
NCT04800133Phase 2
Covid-19 Vaccination in Adolescents and Children
NCT05168709Phase 4
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
NCT05429047
Priming of the NEonatal Immune System by Transfer of Maternal Immunity
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6